D. Jones

发表

Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy

N. Reynolds, V. Hegade, R. Samuel, 2019, The British journal of dermatology.

28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC

R. Chapman, A. Burroughs, K. Kowdley, 2011 .

British Association for the Study of the Liver

A. Perelson, C. Dejong, Y. Ma, 1991 .

Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study

H. Wedemeyer, G. Hirschfield, C. Schramm, 2018 .

Clarity: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Lopixibat Chloride (Formerly Lum001), a Novel Apical Sodium-Dependent Bile Acid Transporter Inhibitor, in the Treatment of Primary Biliary Cirrhosis Associated with Itching

S. Medendorp, B. Bacon, V. Luketic, 2016 .

Approaches to a murine model of AMA positive non-suppurative destructive cholangitis (NSDC)

A. Burt, G. McCaughan, S. Yeaman, 1998 .

971 THE CLINICAL IMPACT OF VARICES AND A NEW EXTERNALLY VALIDATED NON-INVASIVE INEXPENSIVE TOOL TO PREDICT THEIR PRESENCE IN PATIENTS WITH PBC

G. Alexander, M. Hudson, J. Newton, 2012 .

650 Demonstration of the transition of intrahepatic biliary epithelial cells to fibroblasts during chronic inflammatory liver diseases

J. Kirby, H. Robertson, A. Burt, 2006 .

Pre-treatment risk stratification in primary biliary cholangitis: 51st Annual Meeting of the Italian Association for the Study of the Liver – A.I.S.F.

V. Ronca, H. Cordell, S. Taylor-Robinson, 2018 .

Autoimmune hepatitis patients with poor treatment response have a distinct liver transcriptome: implications for personalised therapy

Ben Millar, Kile Green, A. Resteu, 2017 .

Symptoms of autonomic dysfunction in chronic fatigue syndrome.

J. Newton, K. Sutcliffe, O. Okonkwo, 2007, QJM : monthly journal of the Association of Physicians.

603 Correlation between anti-cyp2E1 titre and lymphocyte infiltration in ALD — an autoimmune disease in some patients?

M. Vidali, A. Burt, E. Albano, 2004 .

Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study

Robert L. Martin, D. Bernstein, S. Bergheanu, 2018 .